NewAmsterdam Pharma (NAMS) Net Cash Flow (2023 - 2026)

NewAmsterdam Pharma (NAMS) has 4 years of Net Cash Flow data on file, last reported at -$31.0 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 14.59% year-over-year to -$31.0 million; the trailing twelve-month figure through Mar 2026 stood at -$297.1 million (down 210.95% YoY), and the FY2025 full-year result was -$293.2 million, down 166.92% from the prior year.
• Net Cash Flow climbed to -$31.0 million in Q1 2026, from -$48.3 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $357.0 million in Q4 2024 to a low of -$193.4 million in Q2 2025.
• A 4-year average of $376166.7 and a median of -$30.3 million in 2023 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow jumped 1179.15% in 2024 and slumped 290.43% in 2025, its largest moves.
• Tracing NAMS's Net Cash Flow over 4 years: stood at -$33.1 million in 2023, then jumped by 1179.15% to $357.0 million in 2024, then tumbled by 113.54% to -$48.3 million in 2025, then soared by 35.76% to -$31.0 million in 2026.
• Business Quant data shows NAMS's Net Cash Flow at -$31.0 million in Q1 2026, -$48.3 million in Q4 2025, and -$24.4 million in Q3 2025.